S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline

Summary This publication is the second part of the German‐language S3 guideline on urticaria. It covers the management of urticaria and should be used together with Part 1 of the guideline on classification and diagnosis. This publication was prepared according to the criteria of the AWMF on the basis of the international English‐language S3 guideline with special consideration of health system conditions in German‐speaking countries. Chronic urticaria has a high impact on the quality of life and daily activities of patients. Therefore, if causal factors cannot be eliminated, effective symptomatic treatment is necessary. The recommended first‐line treatment is to administer new generation, non‐sedating H1 antihistamines. If the standard dose is not sufficiently effective, the dose should be increased up to fourfold. For patients who do not respond to this treatment, the second‐line treatment in addition to antihistamines in the treatment algorithm is omalizumab and, if this treatment fails, ciclosporin. Other low‐evidence therapeutic agents should only be used if all treatments in the treatment algorithm agreed upon by the guideline group fail. Both the benefit‐risk profile and cost should be considered. Corticosteroids are not recommended for long‐term treatment due to their inevitable severe side effects.